P939 Safety Outcomes After Fecal Microbiota Transplantation (FMT) For C. difficile Infection (CDI)
Author insight from Desmond Wilson, MD and Colleen R. Kelly, MD, FACG, The Alpert Medical School of Brown University, Providence, RI
What’s new here and important for clinicians?
Our data suggests that adverse events related to fecal microbiota transplant (FMT) for C. difficile infections (CDI) typically manifest as gastrointestinal symptoms that are either transient or mild. Any significant adverse events were likely unrelated to FMT. There has not been a study to our knowledge which highlights the adverse outcomes in the non-immunocompromised patient.
What do patients need to know?
Prior evidence has suggested that FMT is efficacious for patient’s with refractory CDI. One area of obvious concern is safety associated with this procedure. From our data it appears that FMT is generally well tolerated and not associated with acquiring procedure-related infections or serious adverse outcomes.
Author Contact: Desmond Wilson, MD, The Alpert Medical School of Brown University, Providence, RI
Oral 72 Fresh, Frozen, or Lyophilized Fecal Microbiota Transplantation (FMT) for Multiple Recurrent C. difficile Infection (CDI)
P1639 Fecal Microbiota Transplant for Treatment of Refractory C. difficile Colitis: Long-Term Follow-Up of 58 Patients
Oral 71 C. difficile Associated Risk of Death Score (CARDS): A Novel Risk Score to Predict Mortality Among Hospitalized Patients With C. difficile Infection
P454 Outcomes of Fecal Microbiota Transplantation for Clostridium difficile Infection in Patients With Inflammatory Bowel Disease
Media Interview Requests:
Press room and video recording facilities will be available onsite. To arrange an interview with any ACG experts or abstract authors please contact Jacqueline Gaulin of ACG via email firstname.lastname@example.org or by phone at 301-263-9000.